AllQuantitative Report
Argus•April 14, 2021
Argus•April 14, 2021EXEL: What does Argus have to say about EXEL?
Summary
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercial
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Market Digest: FCX, FI, INCY, PG, STX, T, OCApr 25, 2024 •
FI, T, OC, STX, PG, INCY, FCX
- HALO: Raising target price to $41.00Apr 24, 2024 •
HALO
- NBIX: Raising target price to $147.00Apr 24, 2024 •
NBIX
- The Argus Innovation Model PortfolioApr 23, 2024 •
GOOGL, AMAT, AAPL, ANET, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, META, NVDA, SYK, BSX, ORCL, CBOE, PWR, MCK, NOW, LYFT, ADBE, SCHW, MCHP, ISRG, AMZN, ODFL, CRM
- Technical Assessment: Neutral in the Intermediate-TermApr 22, 2024 •
CVX, PFE